NO20074062L - Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn - Google Patents

Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn

Info

Publication number
NO20074062L
NO20074062L NO20074062A NO20074062A NO20074062L NO 20074062 L NO20074062 L NO 20074062L NO 20074062 A NO20074062 A NO 20074062A NO 20074062 A NO20074062 A NO 20074062A NO 20074062 L NO20074062 L NO 20074062L
Authority
NO
Norway
Prior art keywords
prevention
reduction
treatment
combination
baby
Prior art date
Application number
NO20074062A
Other languages
English (en)
Norwegian (no)
Inventor
Robert J Mcmahon
Udo Herz
Josef Neu
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of NO20074062L publication Critical patent/NO20074062L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20074062A 2005-04-15 2007-08-07 Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn NO20074062L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/106,794 US20060233762A1 (en) 2005-04-15 2005-04-15 Method for treating or preventing systemic inflammation in formula-fed infants
PCT/US2006/010415 WO2006113034A1 (en) 2005-04-15 2006-03-22 Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant

Publications (1)

Publication Number Publication Date
NO20074062L true NO20074062L (no) 2007-11-13

Family

ID=36658778

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074062A NO20074062L (no) 2005-04-15 2007-08-07 Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn

Country Status (13)

Country Link
US (2) US20060233762A1 (pt)
EP (1) EP1868596B1 (pt)
KR (1) KR101277050B1 (pt)
CN (1) CN101146525A (pt)
BR (1) BRPI0609401A8 (pt)
CA (1) CA2599618C (pt)
ES (1) ES2738006T3 (pt)
MX (1) MX2007010804A (pt)
MY (1) MY172984A (pt)
NO (1) NO20074062L (pt)
RU (1) RU2416401C2 (pt)
TW (1) TWI372058B (pt)
WO (1) WO2006113034A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572474B2 (en) * 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US20090258823A1 (en) * 2006-12-08 2009-10-15 George Caroline L S Composition and methods for the prevention and treatment of gastrointestinal infections
US9408818B2 (en) * 2007-02-28 2016-08-09 Mead Johnson Nutrition Company Method for the utilization of and product containing inactivated probiotic
CA2704371A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US9439885B2 (en) * 2008-06-03 2016-09-13 Mead Johnson Nutrition Company Method for inhibiting the growth of bacteria
US8498729B2 (en) 2008-08-29 2013-07-30 Smp Logic Systems Llc Manufacturing execution system for use in manufacturing baby formula
CN102985105B (zh) * 2010-01-19 2016-03-09 雅培制药有限公司 包含合生元的营养配方
US10590180B2 (en) * 2015-06-19 2020-03-17 National University Corporation Shizuoka University Immune function development promoter and growth promoter
CN108715822B (zh) * 2018-06-13 2021-09-03 吉林省农业科学院 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用
CN121153868A (zh) * 2025-11-21 2025-12-19 四平君乐宝乳业有限公司 适用于食物蛋白过敏婴儿的特殊医学用途配方食品组合物用于改善嗜酸性粒细胞性食管炎的非治疗目的的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
ATE265207T1 (de) * 1997-02-21 2004-05-15 Abbott Lab Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CA2351469A1 (en) * 1998-12-15 2000-06-22 Susan Marie Kaup Method and composition for the maintenance and restitution of gut integrity
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20030203839A1 (en) * 1999-10-29 2003-10-30 Kruzel Marian L. Immune enhancing composition containing lactoferrin
US20010047036A1 (en) * 1999-12-17 2001-11-29 Vanderhoof Jon A. Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome
AU2001233529A1 (en) * 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
JP2003535903A (ja) * 2000-06-19 2003-12-02 ミューコプロテック・プロプライエタリー・リミテッド プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP3853673B2 (ja) * 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
ATE433674T1 (de) * 2003-06-23 2009-07-15 Nestec Sa Säuglingsnährpräparat oder folgemilch
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12

Also Published As

Publication number Publication date
EP1868596A1 (en) 2007-12-26
CA2599618A1 (en) 2006-10-26
KR101277050B1 (ko) 2013-06-25
US20070009495A1 (en) 2007-01-11
BRPI0609401A8 (pt) 2018-03-13
CA2599618C (en) 2015-04-28
TWI372058B (en) 2012-09-11
ES2738006T3 (es) 2020-01-17
US20060233762A1 (en) 2006-10-19
MY172984A (en) 2019-12-17
MX2007010804A (es) 2007-09-26
RU2007133444A (ru) 2009-05-20
EP1868596B1 (en) 2019-05-15
KR20080025660A (ko) 2008-03-21
RU2416401C2 (ru) 2011-04-20
WO2006113034A1 (en) 2006-10-26
CN101146525A (zh) 2008-03-19
BRPI0609401A2 (pt) 2010-03-30
TW200716146A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
NO20074062L (no) Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn
WO2010070675A8 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
MX2008001503A (es) Composicion cosmetica o dermatologica para la prevencion o el tratamiento de piel sensible o seca.
WO2010068794A3 (en) Hif inhibitors and use thereof
BRPI0916693A2 (pt) uso de uma quantidade eficaz de pelo menos um microorganismo probiótico, composição cosmética e/ou dermatológica, e, método de tratamento cosmético
WO2006131737A3 (en) Method and composition for treating inflammatory disorders
EP4382129A3 (en) Compounds for fast and efficient click release
PH12012502016A1 (en) Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
NZ595706A (en) L-ornithine phenyl acetate and methods of making thereof
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
EP3330252A3 (en) Isoprenyl compounds and methods thereof
BRPI1010369B8 (pt) composição cosmética em forma de nanoemulsão óleo-em-água e uso de uma composição
NO20074550L (no) Anvendelse av Lactobacillus Rhamnosus GG for behandling, forebygging eller reduksjon av systemisk inflamasjon hos et spebarn matet med morsmelkerstatning
AU2003232722A1 (en) Polyunsaturated linear aldehydes and their derivatives with anti-radical and anti-tumoral activity
WO2007081878A8 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
WO2005112915A3 (en) Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs
NO20080034L (no) Benzotiazol-2-on derivater som lipase og fosfolipaseinhibitorer
NZ599521A (en) Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
WO2009017161A1 (ja) 炎症性サイトカインの抑制剤
EP2340724A3 (en) Treatment of stressed patients
BRPI0514600A (pt) métodos para a fabricação de um composto, para a purificação de um composto, para o tratamento de um indivìduo tendo uma condição neoplástica, tendo carcinoma de célula escamosa, e tendo carcinoma de célula basal, para a redução ou prevenção da ocorrência de uma condição neoplástica em um indivìduo, e para a redução de triglicerìdeos no soro em um indivìduo, composto, e, composição farmacêutica
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders
WO2006090388A3 (en) Fruit cell culture extract for treating inflammation

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MJN U.S. HOLDINGS LLC, US

FC2A Withdrawal, rejection or dismissal of laid open patent application